Niagen Bioscience/$NAGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Ticker
$NAGE
Sector
Primary listing
Employees
104
Headquarters
Website
NAGE Metrics
BasicAdvanced
$554M
32.20
$0.22
2.13
-
Price and volume
Market cap
$554M
Beta
2.13
52-week high
$14.69
52-week low
$3.18
Average daily volume
1M
Financial strength
Current ratio
3.882
Quick ratio
3.161
Long term debt to equity
3.628
Total debt to equity
5.128
Profitability
EBITDA (TTM)
17.452
Gross margin (TTM)
63.62%
Net profit margin (TTM)
15.24%
Operating margin (TTM)
14.33%
Effective tax rate (TTM)
3.28%
Revenue per employee (TTM)
$1,120,000
Management effectiveness
Return on assets (TTM)
14.32%
Return on equity (TTM)
37.36%
Valuation
Price to earnings (TTM)
32.198
Price to revenue (TTM)
4.618
Price to book
8.61
Price to tangible book (TTM)
8.65
Price to free cash flow (TTM)
25.655
Free cash flow yield (TTM)
3.90%
Free cash flow per share (TTM)
0.27
Growth
Revenue change (TTM)
35.89%
Earnings per share change (TTM)
-816.96%
3-year revenue growth (CAGR)
18.98%
10-year revenue growth (CAGR)
19.40%
3-year earnings per share growth (CAGR)
-19.63%
10-year earnings per share growth (CAGR)
8.76%
What the Analysts think about NAGE
Analyst ratings (Buy, Hold, Sell) for Niagen Bioscience stock.
Bulls say / Bears say
Niagen Bioscience achieved 38% year-over-year net sales growth in Q1 2025, reaching $30.5 million, driven by strong results from both its Tru Niagen consumer supplement and Niagen® ingredient segments. (Nasdaq)
The company became profitable in Q1 2025, reporting net income of $5.1 million and adjusted EBITDA of $4.9 million, with gross margin rising to 63.4%, showing improving operational leverage. (Nasdaq)
In March 2025, Niagen Bioscience expanded its intellectual property portfolio with a new patent covering nicotinamide riboside (NR) salt compositions, strengthening its technological leadership in NAD+ precursor innovation. (Nasdaq)
Q1 2025 net sales were generated exclusively from the Tru Niagen consumer supplement (70.5%) and Niagen® ingredient (26.2%) segments, highlighting limited revenue diversification beyond NAD+ therapies. (Nasdaq)
The company expects general and administrative expenses to increase by $7–8 million in 2025 due to higher share-based compensation, which could put pressure on profitability if revenue growth slows. (Nasdaq)
Niagen Bioscience’s drug development pipeline remains early-stage, as its BIO 2025 participation focused only on starting partnership talks for emerging candidates, indicating limited internal late-stage assets. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
NAGE Financial Performance
Revenues and expenses
NAGE Earnings Performance
Company profitability
NAGE News
AllArticlesVideos
Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide
Business Wire4 days ago
AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+
Business Wire3 weeks ago
Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Niagen Bioscience stock?
Niagen Bioscience (NAGE) has a market cap of $554M as of October 05, 2025.
What is the P/E ratio for Niagen Bioscience stock?
The price to earnings (P/E) ratio for Niagen Bioscience (NAGE) stock is 32.2 as of October 05, 2025.
Does Niagen Bioscience stock pay dividends?
No, Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders as of October 05, 2025.
When is the next Niagen Bioscience dividend payment date?
Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Niagen Bioscience?
Niagen Bioscience (NAGE) has a beta rating of 2.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.